Noven Pharmaceuticals Cited for Quality Deficiencies

Drug GMP Report
A A
The FDA issued a Form 483 to Noven Pharmaceuticals after observing numerous problems at the transdermal drug manufacturer’s Miami, Florida facility.

To View This Article:

Login

Subscribe To Drug GMP Report